Every patient deserves endocrine clinical assessment, but not every patient needs an indiscriminate hormone panel before obesity treatment begins.
Normal fasting glucose or HbA1c can coexist with hyperinsulinemia, visceral adiposity, fatty liver, hypertension, dyslipidemia, sleep apnea, and rising cardiovascular risk.
There is no universal hidden panel for obesity. The valuable tests are those that detect complications, identify selected secondary causes, establish treatment safety, or change the level of intervention.
Two people can eat apparently identical foods and show different weight trajectories because total exposure, absorption, body size, spontaneous activity, appetite compensation, sleep, genetics, microbiome, and measurement error differ.
Many clinics identify excess weight and immediately sell a protocol. They do not establish the phenotype, drivers, complications, functional burden, or treatment history that a real obesity diagnosis requires.